BioSpace News Archive

Rapid Dose Therapeutics Corp. (“ RDT ” or the “ Company ”) ( CSE: DOSE ), a Canadian biotechnology company revolutionizing drug delivery through innovation, is one of five Canadian companies accepted into this year’s Venture Mentoring Services program offered by the Maryland Tech Council (MTC) in partnership with the Canadian Trade Commissioner Service in Washington, DC.

CareDx, Inc. today announced it will host a symposium to describe the latest innovations in post-cardiac transplant care at the HFSA (Heart Failure Society of America) Annual Scientific Meeting 2022 taking place in Washington, D.C., September 30 - October 3.

NEXGEL, Inc. announced today that the Company has appointed Dr. Neil Chesen and Dr. Leonard Nelson to its Scientific Advisory Board.

SIGA Technologies, Inc. today announced that the U.S. Department of Defense (DoD) awarded a new contract to SIGA for the procurement of up to $10.7 million of oral TPOXX.

Axsome Therapeutics, Inc. announced that, following a Type A meeting with the U.S. Food and Drug Administration (FDA), it intends to resubmit its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine in the third quarter of 2023.

Wellbeing Digital Sciences Inc. announces that Najla Guthrie, CEO of Wellbeing, will participate in the Cantor Fitzgerald Mental Health Clinics Symposium to be held virtually on October 11, 2022 at 9:00 a.m. ET.

Recludix Pharma announced the appointment of Matthew Caldemeyer as chief business officer.

Lisata Therapeutics, Inc. announced that Erkki Ruoslahti, M.D., Ph.D., the scientific founder of the Company’s CendR Platform™ technology and a member of the Company’s board of directors, was a recipient of the 2022 Albert Lasker Basic Medical Research Award, which was awarded on September 28, 2022.

BioVie Inc. announced the participation of its management team in a panel discussion and one-on-one investor meetings at Cantor Fitzgerald’s Neurology & Psychiatry Conference, to be held October 6-7, 2022, in San Francisco, CA.

Meliora Therapeutics announced today the close of an $11M seed financing round led by HOF Capital and ZhenFund, with participation from Obvious Ventures, Village Global, BrightEdge.